Zelluna ASA
Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101); and collaboration with Etcembly Ltd for AI-enabled TCR engineering. The company was founded in 2016 and is based in Oslo, Norway.
Zelluna ASA (ZLNA) - Total Assets
Latest total assets as of December 2025: Nkr103.50 Million NOK
Based on the latest financial reports, Zelluna ASA (ZLNA) holds total assets worth Nkr103.50 Million NOK as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zelluna ASA - Total Assets Trend (2021–2025)
This chart illustrates how Zelluna ASA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zelluna ASA - Asset Composition Analysis
Current Asset Composition (December 2025)
Zelluna ASA's total assets of Nkr103.50 Million consist of 83.0% current assets and 17.1% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 75.7% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr14.00 Million | 13.5% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Zelluna ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zelluna ASA's current assets represent 83.0% of total assets in 2025, a decrease from 88.8% in 2021.
- Cash Position: Cash and equivalents constituted 75.7% of total assets in 2025, down from 87.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 10.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 13.5% of total assets.
Zelluna ASA Competitors by Total Assets
Key competitors of Zelluna ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Zelluna ASA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zelluna ASA generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zelluna ASA is currently not profitable relative to its asset base.
Zelluna ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.87 | 3.62 | 7.84 |
| Quick Ratio | 4.87 | 3.62 | 7.84 |
| Cash Ratio | 4.44 | 0.00 | 0.00 |
| Working Capital | Nkr68.21 Million | Nkr 82.36 Million | Nkr 155.40 Million |
Zelluna ASA - Advanced Valuation Insights
This section examines the relationship between Zelluna ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.32 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | Nkr103.50 Million |
| Market Capitalization | $19.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zelluna ASA's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zelluna ASA's assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zelluna ASA (2021–2025)
The table below shows the annual total assets of Zelluna ASA from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr103.50 Million | -10.67% |
| 2024-12-31 | Nkr115.86 Million | -66.81% |
| 2023-12-31 | Nkr349.04 Million | -31.52% |
| 2022-12-31 | Nkr509.67 Million | -22.25% |
| 2021-12-31 | Nkr655.54 Million | -- |